Aurora BioScience Neurology

VNS Therapy for Pharmacoresistant Epilepsy

 

This resource is intended to provide specific information regarding VNS Therapy™ and pharmacoresistant epilepsy for physicians, nurses and other healthcare professionals.

 

 

 VNS Therapy has demonstrated significant success in treating patients with learning disability and epilepsy.¹

A recently published article in Neurology reported that 70.5% of all the paediatric patients included in the VNS Therapy Patient Registry had learning disabilities. Sixty-one percent of the paediatric patients treated with VNS Therapy had at least a 50% reduction in seizure frequency after 12 months.¹